Completed PHASE2 INTERVENTIONAL 2-arm NCT02107950

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma

Sponsor: SOTIO a.s.

Conditions Ovarian Cancer (OvCa) Ovarian Epithelial Cancer Ovarian Neoplasms

Interventions DCVAC/OvCa in parallel with chemotherapy Standard of Care

Updated 12 times since 2017 Last updated: Aug 13, 2018 Started: Nov 30, 2013 Primary completion: Nov 30, 2016 Completion: May 17, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ovarian Cancer (OvCa) and Ovarian Epithelial Cancer and is currently completed. SOTIO a.s. leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2
Nov 2021 — Sep 2023 [monthly]

Completed PHASE2

▶ Show 7 earlier versions

Jan 2021 — Nov 2021 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2018 — May 2018 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SOTIO a.s.

Data source: Sotio Biotech Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bialystok, Poland , Brno, Czechia , Cologne, Germany , Dresden, Germany , Erlangen, Germany , Hradec Králové, Czechia , Krakow, Poland , Lublin, Poland , Nový Jičín, Czechia , Olomouc, Czechia and 4 more locations